Compounded tirzepatide vials went out across the country without assurance they were sterile

Houston Rx LLC, a compounding firm in Houston, Texas, is recalling 64 vials of compounded tirzepatide and niacinamide injection because the sterility of the product could not be assured. The vials were distributed nationwide in the United States. The U.S. Food and Drug Administration put the recall in its enforcement report dated October 21, 2026, as a Class II action.

Help yourself and the planet: The Cool Down makes it easy to help yourself while helping the planet, with smart, simple changes to save more and waste less in your everyday life.

Get The Cool Down →

We may earn a commission if you sign up.

Houston Rx began the recall on September 25, 2026. FDA classified it on October 13, and the entry still reads ongoing.

The vials, the lot and the count

The entry is recall number D-0040-2027, listed in the agency’s October 21 enforcement report. The product is described as Tirzepatide/Niacinamide, a 2 mL vial at 40 mg per vial, injection labeled 20mg/2mg/mL, prescription only, from Houston Rx LLC at 15430 Vantage Parkway E, Suite 220. One lot is named, TZN-080326-20/2-2, with a beyond use date of December 1, 2026. Compounded drugs carry a beyond use date set by the compounder rather than a manufacturer’s expiration date. The record lists the quantity as 64 vials, the reason as lack of assurance of sterility, and the action as voluntary and firm-initiated. The firm notified customers by two or more channels, including email, fax, letter, press release, telephone or visit.

Sixty-four vials is a small number set beside the other recalls in the same report. The word nationwide describes where those vials went, not how many there were. The same event, number 99990, also holds a separate recall, D-0041-2027, of 7 vials of compounded sermorelin, lot SER-081726-1-10, but that entry cites lack of process control and not sterility, so the sterility finding attaches only to the tirzepatide.

What compounded status means for oversight

FDA’s compounding policy page says plainly that compounded drugs are not FDA-approved and that the agency does not review them for safety, effectiveness or quality before they reach patients. Under section 503A of the federal food and drug law, a compounded product is exempt from several requirements when it is made from a valid patient-specific prescription, while outsourcing facilities, unlike 503A compounders, must follow current good manufacturing practice. The enforcement record does not say which category Houston Rx falls into, so that question stays open here.

The agency’s Center for Drug Evaluation and Research explains the stakes on its page on the risks of compounded drugs. If a compounded drug fails quality standards, such as when it is contaminated, it could cause serious injury or death, and the agency continues to investigate many reports of serious adverse events tied to contaminated or poor-quality compounded products. Separately, FDA’s statement on unapproved GLP-1 drugs reports that, as of May 31, 2026, it had received 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide, and says the true totals are likely higher because of underreporting. Those counts cover all kinds of events, including dosing errors, and are not tied to this lot.

Tirzepatide and niacinamide appear together on the label, and the strength is written as 20mg/2mg/mL, which together with the 2 mL vial size gives the 40 mg per vial that the record also states. The pairing of a weight-management ingredient with a vitamin is typical of preparations sold by compounding pharmacies, and the enforcement record describes the product only by name, strength and lot. It contains no information about the prescribers who ordered it, the patients who received it, or how many states the 64 vials reached beyond the single word nationwide.

What a lack of assurance does and does not mean

The wording matters. A lack of assurance of sterility means the firm or FDA could not demonstrate that the vials were free of microbial contamination. It is not a finding that any vial was contaminated, and the record reports no positive test and no illness. Class II, by the agency’s definition, covers cases where serious adverse health consequences are remote.

Timing shapes the practical risk. The lot’s beyond use date falls on December 1, 2026, about five weeks after the report, and a compounded vial has no long shelf life to run out the clock on. Any of the 64 vials dispensed in the weeks after the September 25 recall start may already have been used or discarded. FDA’s GLP-1 statement also advises using multi-dose vials of sterile medication within 28 days of first use, which narrows the window further for anyone who received one. The same statement tells patients to use a new sterile needle and syringe for each dose and not to use any injectable GLP-1 drug that arrives warm, since shipping temperature can affect quality.

Neither the Houston Rx entry nor FDA’s report names a company officer, a pharmacist in charge or an agency official, so the account rests on the enforcement record alone. It does not say how many of the 64 vials reached patients, in which states, or what led the firm to lose confidence in sterility before it started the recall on September 25. openFDA labels its enforcement rows unvalidated and unfit for medical decisions, so the listing functions as notice that a problem exists rather than as a finding about any single vial, and a patient holding one is pointed back to the clinic or pharmacy that dispensed it.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

Help yourself and the planet: Get The Cool Down →

We may earn a commission if you sign up.